Home › Research › Drug development
Education and Alzheimer Disease Genetic Risk in Associations of GLP-1 Receptor Agonists With Dementia Among Adults With Type 2 Diabetes
Wang J, Pederson AM, Flanders MD, Choi M, Buto P, Sims KD, Chen R, Couch E et al.. medRxiv, 2026-09-08
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective To evaluate whether educational attainment and Alzheimer disease genetic risk were associated with GLP-1 receptor agonist initiation and dementia incidence and whether adjustment for these measured factors materially changed the estimated association between GLP-1 receptor agonist initiation and incident dementia among adults with type 2 diabetes. Research Design and Methods We conducted an observational cohort study using linked electronic health record, survey, and genetic data from 14,364 All of Us Research Program participants with type 2 diabetes. We estimated associations of educational attainment and Alzheimer disease genetic risk with treatment initiation and incident dementia and compared GLP-1 receptor agonist initiators with initiators of non-sodium-glucose cotransporter 2 inhibitor second-line therapies, with a separate sodium-glucose cotransporter 2 inhibitor compa
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 14,364 participants. This observational cohort study used data from 14,364 All of Us Research Program participants with type 2 diabetes to examine whether educational attainment and Alzheimer disease genetic risk were associated with GLP-1 receptor agonist initiation and dementia incidence. Reported effect size: 54.2%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wang, J., Pederson, A. M., Flanders, M. D., Choi, M., Buto, P., Sims, K. D., et al. (2026). Education and Alzheimer Disease Genetic Risk in Associations of GLP-1 Receptor Agonists With Dementia Among Adults With Type 2 Diabetes. medRxiv. https://doi.org/10.64898/2026.09.04.26362304
Vancouver
Wang J, Pederson AM, Flanders MD, Choi M, Buto P, Sims KD, et al. Education and Alzheimer Disease Genetic Risk in Associations of GLP-1 Receptor Agonists With Dementia Among Adults With Type 2 Diabetes. medRxiv. 2026. doi:10.64898/2026.09.04.26362304.
BibTeX
@article{wang2026-dbbc063a,
author = {Wang, J. and Pederson, A. M. and Flanders, M. D. and Choi, M. and Buto, P. and Sims, K. D. and Chen, R. and Couch, E. and others},
title = {{Education and Alzheimer Disease Genetic Risk in Associations of GLP-1 Receptor Agonists With Dementia Among Adults With Type 2 Diabetes}},
journal = {medRxiv},
year = {2026},
doi = {10.64898/2026.09.04.26362304},
url = {https://doi.org/10.64898/2026.09.04.26362304}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Research Design and Methods We conducted an observational cohort study using linked electronic health record, survey, and genetic data from 14,364 All of Us Research Program participants with type 2 diabetes.
- We estimated associations of educational attainment and Alzheimer disease genetic risk with treatment initiation and incident dementia and compared GLP-1 receptor agonist initiators with initiators of non-sodium-glucose cotransporter 2 inhibitor second-line therapies, with a separate sodium-glucose cotransporter 2 inhibitor comparison.
- Models were estimated before and after additional adjustment for educational attainment, APOE ε4, and non-APOE genetic risk.
- Results Among 14,364 participants (mean age, 60.2 years; 54.2% female), the mean follow-up duration was 4.3 years.
Why it matters
This observational cohort study used data from 14,364 All of Us Research Program participants with type 2 diabetes to examine whether educational attainment and Alzheimer disease genetic risk were associated with GLP-1 receptor agonist initiation and dementia incidence. It compared GLP-1 receptor agonist initiators with initiators of other second-line therapies to assess the estimated association with incident dementia.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcohort study
- Participants14,364
- Effect size54.2%
- Evidence strengthModerate
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 40 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 38 of the 94 points we could judge it on, which is 40 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 4 / 4 | 14,364 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Sarah F. Ackley: h-index 22 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 38 / 94 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 38 of the 94 points we could judge it on is 40 out of 100. |
| Total | 40 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Drug development from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.